Riskpilot← Back to searchSign inGet full accessMyonex ApS
APSActiveCVR 39905094Sundkrogsgade 21Wholesale of pharmaceutical and medical goods · NACE 4646Est. 2018— employees
Revenue 2024
DKK 2,6M
-2% vs 2023
EBITDA margin
100.0%
-2% vs 2023
Equity ratio
98.1%
Financial strength
Net profit 2024
DKK 2,2M
+13% vs 2023
| Revenue | DKK 2,6M | -2% |
| EBITDA | DKK 2,6M | -2% |
| Net profit | DKK 2,2M | +13% |
| Total assets | DKK 19,3M | -3% |
| Equity | DKK 18,9M | +13% |
| Employees | — | — |
Legal name
Myonex ApS
CVR number
39905094
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
28. september 2018
Share capital
DKK 50.000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er indkøb, distribution og styring af komparatormedicin og farmaceutiske forsyninger til kliniske forsøg, herunder bioteknologiske studier, og anden hertil forbundet aktivitet.
Address
Sundkrogsgade 21
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | -618 | -104 | 8.057.814 | 11.411 | 2.654 | 2.592 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -618 | -104 | 8.057.814 | 11.411 | 2.654 | 2.592 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -618 | -104 | 8.057.814 | 11.411 | 2.654 | 2.592 |
| Net financials | -16 | -1 | -114.219 | -165 | -176 | 131 |
| Profit before tax | -635 | -105 | 7.943.595 | 11.246 | 2.478 | 2.723 |
| Tax | -0 | -0 | 1.705.836 | 2.490 | 568 | 568 |
| Net profit | -635 | -105 | 6.237.759 | 8.756 | 1.909 | 2.155 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 4.262 | 3.678 | 18.101.548 | 17.050 | 19.908 | 19.307 |
| Equity | -585 | -179 | 6.115.100 | 14.871 | 16.781 | 18.936 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 4.846 | 3.856 | 11.986.448 | 2.179 | 3.128 | 371 |
| Total debt | 4.846 | 3.856 | 11.986.448 | 2.179 | 3.128 | 371 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20192024
Equity ratio
98.1%
This company
38.2%
Market median
+157% vs market
20192024
Return on equity
11.4%
This company
18.4%
Market median
+38% vs market
20192024
Net profit margin
83.2%
This company
8.1%
Market median
+927% vs market
20192024
Asset turnover
0.13×
This company
1.12×
Market median
-88% vs market
20192024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20192024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2018-09-28 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MA Management | Management | 2018 | — | — |
JW Management | Management | 2022 | — | — |
GT Management | Management | 2022 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Myonex ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Michael Allen Cohen | Management | 0 companies |
| James Whitfield Lovett | Management | 0 companies |
| Gregory Thomas Lavin | Management | 0 companies |